Page 42 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 42
Chapter 2
21. Mack B, Gires O. CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE. 2008;3:e3360.
22. Boellaard R, Hoekstra O, Lammertsma A. Software tools for standardized analysis of FDG whole body
studies in multi-center trials. J Nucl Med. 2008;49:159P-159P.
23. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software
for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
24. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med.
1993;34:689-694.
25. Plaizier MA, Roos JC, Teule GJ, et al. Comparison of non-invasive approaches to red marrow dosimetry
for radiolabelled monoclonal antibodies. Eur J Nucl Med. 1994;21:216-222.
26. Jones WF, Digby WM, Luk WK, Casey ME, Byars LG. Optimizing rod window width in positron
emission tomography. IEEE Trans Med Imaging. 1995;14:266-270.
27. Tatsumi M, Clark PA, Nakamoto Y, Wahl RL. Impact of body habitus on quantitative and qualitative
image quality in whole-body FDG-PET. Eur J Nucl Med Mol Imaging. 2003;30:40-45.
28. Botkin CD, Osman MM. Prevalence, challenges, and solutions for (18)F-FDG PET studies of obese
patients: a technologist’s perspective. J Nucl Med Technol. 2007;35:80-83.
29. Halpern BS, Dahlbom M, Quon A, et al. Impact of patient weight and emission scan duration on PET/
CT image quality and lesion detectability. J Nucl Med. 2004;45:797-801.
30. Halpern BS, Dahlbom M, Auerbach MA, et al. Optimizing imaging protocols for overweight and obese
patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005;46:603-607.
31. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: detection of colorectal carcinoma
with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 1995;36:1818-1824.
32. Cutler PD, Schwarz SW, Anderson CJ, et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3
as determined by PET imaging of the torso. J Nucl Med. 1995;36:2363-2371.
40
